SCHEMBL2834010

SCHEMBL2834010

Cc1c(C(=O)O)c2ccccc2c(=O)n1C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.56
ALOX15 P16050 1/20 0.56
ALDH1A1 P00352 5/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ATM Q13315 1/20 0.49
KDM4E B2RXH2 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPSR1 Q6W5P4 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GRM1 Q13255 1/20 0.44
TSHR P16473 2/20 0.42
CRHBP P24387 2/20 0.42
CRHR2 Q13324 2/20 0.42
POLB P06746 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
LMNA P02545 2/20 0.41
XBP1 P17861 1/20 0.41
MAPK1 P28482 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834608 0.99 GAA (0.53) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL2834061 0.96 GAA (0.50) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL2833992 0.93 MEN1 (0.46) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL27735261 0.84 GAA (0.55) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL16344718 0.83 GAA (0.53) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL7951037 0.79 TACR3 (0.51) ALDH1A1MEN1KMT2AATMNPSR1
SCHEMBL27718459 0.77 ESR1 (0.44) GAAALOX15ALDH1A1MEN1KMT2A
SCHEMBL2156483 0.77 TACR3 (0.50) ALDH1A1MEN1KMT2AATMNPSR1
SCHEMBL16344498 0.76 PDE4B (0.44) GAAALOX15ALDH1A1TSHRHSD17B10
SCHEMBL4374054 0.75 MEN1 (0.42) GAAALOX15ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 GAA 1411/4885ALOX15 2951/4885ALDH1A1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.